tiprankstipranks
Defence Therapeutics (DTCFF)
OTHER OTC:DTCFF
US Market
DTCFF
Defence Therapeutics
RESEARCH TOOLSreports
Want to see DTCFF full AI Analyst Report?

Defence Therapeutics (DTCFF) Income Statement

27 Followers

Defence Therapeutics Income Statement

Last quarter (Q2 2026), Defence Therapeutics's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q2, Defence Therapeutics's net income was C$-1.52M. See Defence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Sep 25Jun 24Sep 23Sep 22Sep 21
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -72.34KC$ -90.92KC$ -13.82KC$ 0.00C$ 0.00
Operating Expenses
C$ 3.20MC$ 12.66MC$ 6.48MC$ 3.56MC$ 2.86M
Depreciation and Amortization
C$ 72.34KC$ 70.94KC$ 13.82KC$ 7.27MC$ 2.83M
EBITDA
C$ -3.13MC$ -12.68MC$ -6.48MC$ 0.00C$ 0.00
Operating Income
C$ -3.27MC$ -12.66MC$ -6.55MC$ -3.56MC$ -2.86M
Other Income/Expenses
C$ -253.20KC$ -537.24KC$ -322.42KC$ -3.78MC$ 0.00
Pretax Income
C$ -3.52MC$ -13.19MC$ -6.87MC$ -7.34MC$ -2.86M
Net Income
C$ -3.52MC$ -13.19MC$ -6.76MC$ -7.34MC$ -2.86M
Per Share Metrics
Basic EPS
C$ -0.07C$ -0.30C$ -0.17C$ -0.20C$ -0.11
Diluted EPS
C$ -0.07C$ -0.30C$ -0.17C$ -0.20C$ -0.11
Weighted Average Shares Outstanding
 49.83M 44.63M 39.66M 36.08M 26.60M
Weighted Average Shares Outstanding (Diluted)
 49.83M 44.63M 39.66M 36.08M 26.60M
Currency in CAD

Defence Therapeutics Earnings and Revenue History